Amgen SupportPlus
Amgen offers assistance to patients through Amgen SupportPlus Co-Pay Program, and the Amgen Safety Net Foundation. A complete list of Amgen oncology products and their related assistance programs is provided in the Table.
Amgen SupportPlus Co-Pay Program
This program can help your eligible commercially insured patients cover their out-of-pocket prescriptions costs. Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.
Patients can register for this program by visiting AmgenSupportPlus.com. For more information, call 866-264-2778.
Amgen Safety Net Foundation
This foundation assists patients who are uninsured or their insurance plan excludes the prescribed Amgen medicine or its generic/biosimilar. To apply to the Amgen Safety Net Foundation, visit www.amgensafetynetfoundation.com and select the prescribed medicine.
TABLE Amgen Oncology/Supportive Care Drugs
Kyprolis (carfilzomib) Indications
Mvasi (bevacizumab-awwb) Indications
- Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
- Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
- Unresectable, locally advanced, recurrent or metastatic non-squamous non–small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
- Recurrent glioblastoma in adults.
- Metastatic renal cell carcinoma in combination with interferon-alfa.
- Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer:
- in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection
- in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens
- in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease
Neupogen (filgrastim)
Nplate (romiplostim) Indications
Riabni (rituximab-arrx) Indications
Adult patients with non-Hodgkin lymphoma (NHL), including relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy; in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; nonprogressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens; treatment of adult patients with chronic lymphocytic leukemia (CLL), including previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide